Dale J. Kempf
Global Pharmaceutical Research & Development Division Abbott
Abbott Park
USA
Name/email consistency: high
- Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir. Kempf, D.J., Klein, C., Chen, H.J., Klein, L.L., Yeung, C., Randolph, J.T., Lau, Y.Y., Chovan, L.E., Guan, Z., Hernandez, L., Turner, T.M., Dandliker, P.J., Marsh, K.C. Antivir. Chem. Chemother. (2007)
- Practical preclinical model for assessing the potential for unconjugated hyperbilirubinemia produced by human immunodeficiency virus protease inhibitors. Kempf, D.J., Waring, J.F., Morfitt, D.C., Werner, P., Ebert, B., Mitten, M., Nguyen, B., Randolph, J.T., DeGoey, D.A., Klein, L.L., Marsh, K. Antimicrob. Agents Chemother. (2006)
- Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. Kempf, D.J., King, M.S., Bernstein, B., Cernohous, P., Bauer, E., Moseley, J., Gu, K., Hsu, A., Brun, S., Sun, E. J. Infect. Dis. (2004)
- Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Kempf, D.J., Isaacson, J.D., King, M.S., Brun, S.C., Sylte, J., Richards, B., Bernstein, B., Rode, R., Sun, E. Antivir. Ther. (Lond.) (2002)
- Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. Kempf, D.J., Isaacson, J.D., King, M.S., Brun, S.C., Xu, Y., Real, K., Bernstein, B.M., Japour, A.J., Sun, E., Rode, R.A. J. Virol. (2001)
